1. Kita-Sommers Profiles | Facebook
People named Kita Sommers. Katie Sommers. Lives in Denver, Colorado. View profile. Katie Somers. Lives in Oregon, Ohio. View profile. Catte De Haut Sommet.
See posts, photos and more on Facebook.
2. All services | Lansing - McCoy's Guide
Kitra Somers. Picture of Kitra Somers. Escorts. in Lansing. Hotel incalls & outcalls in and around Lansing. (001) 517 803 7793. Adult Services. Recently added ...
To receive the Free 7 Day Membership Offer simply leave a legitimate review for any of our advertisers and we will credit your account with 7 days Premium Membership for free!
3. External Redirect | Bukkit Forums
https://telegra.ph/kitra-somers--Kitra-Somers-Sensualist-Extraordinaire-on-Twitter-03-24. You are about to leave Bukkit Forums and visit a site we have no ...
https://telegra.ph/kitra-somers--Kitra-Somers-Sensualist-Extraordinaire-on-Twitter-03-24
4. Geen titel
CyberCTM - https://telegra.ph/Kitra-Somers-Therapist-on-Twitter-whos-hitting-the-gym-Amanda-Greenes-Instagram-Twitter-Facebook-on-IDCrawl-01-14.
CyberCTM - https://telegra.ph/Kitra-Somers-Therapist-on-Twitter-whos-hitting-the-gym-Amanda-Greenes-Instagram-Twitter-Facebook-on-IDCrawl-01-14
5. Encounter: Kitra returns! - ECCIE Worldwide
Default Encounter: Kitra returns! User ID: - Date: First week of March Name: Kitra Somers Phone: 5176040048. Email Address: KitraSomers@gmail.com. URL ...
Encounter: Kitra returns! Encounter Reports - Michigan
6. Redirect Warning - Marble Brewery
https://telegra.ph/kitra-somers--35-Instagram-Captions-For-S-mores-Because-It-s-Always-S-more-03-13. Continue or Cancel.
You’re opening a new web page going to host telegra.ph that is not part of Marble Brewery.
7. [PDF] Human DUX4 and mouse Dux interact with STAT1 and broadly inhibit ...
CIC or the Kitra-SRS CIC-DUX4 fusion protein in ... The Kitra-SRS cells (RRID:CVCL_YI69) were provided by Dr. ... Somers, G. R. (2012). The CIC-DUX4. 780 fusion ...
8. Human DUX4 and mouse Dux interact with STAT1 and broadly inhibit ...
We confirmed that the Kitra-SRS sarcoma cell line expresses a CIC-DUX4 fusion mRNA containing the terminal 98 amino acids of DUX4 as previously described (Nakai ...
DUX4 activates the first wave of zygotic gene expression in the early embryo. Mis-expression of DUX4 in skeletal muscle causes facioscapulohumeral dystrophy (FSHD), whereas expression in cancers suppresses IFNγ induction of major histocompatibility ...
9. [PDF] Show Jumping Results - Equimillion
2 okt 2023 · KITRA PARK PETCH. ZAKYNTHOS PRIPECHO. Jett Newman. 2. 34. 29. 7. 5. 60. 316 ... Brooke Somers. 6. 30. 29. 7. 5. 59. 278. RADISH J. JUST RADISH.
10. Human DUX4 and mouse Dux interact with STAT1 and broadly inhibit ...
24 apr 2023 · We confirmed that the Kitra-SRS sarcoma cell line expresses a CIC-DUX4 fusion mRNA containing the terminal 98 amino acids of DUX4 as previously ...
The developmental transcription factor DUX4 interacts with STAT1 and broadly suppresses expression of IFNγ-stimulated genes.
11. [PDF] 2016 ANNUAL REPORT - Boys & Girls Clubs of Bloomington
Ludlow, Kitra. Lueken, Joseph & Pamela. Lukens, John & Cassie ... Smith & Suhr Merrill Lynch. Smithville Charitable Foundation. Snow, Jeff & Lora. Somers, Alan.
12. Human DUX4 and mouse Dux interact with STAT1 and broadly inhibit ...
11 aug 2022 · (B, left panel) RT-qPCR of the indicated genes in MB135 parental or Kitra ... , & Somers, G. R. (2012). The CIC-DUX4 ... The Kitra-SRS sarcoma cell ...
DUX4 activates the first wave of zygotic gene expression in the early embryo. Mis-expression of DUX4 in skeletal muscle causes facioscapulohumeral dystrophy (FSHD), whereas expression in cancers suppresses IFNγ-induction of MHC Class I and contributes to immune evasion. We show that the DUX4 protein interacts with STAT1 and broadly suppresses expression of IFNγ stimulated genes by decreasing bound STAT1 and Pol-II recruitment. Transcriptional suppression of ISGs requires conserved (L)LxxL(L) motifs in the carboxyterminal region of DUX4 and phosphorylation of STAT1 Y701 enhances interaction with DUX4. Consistent with these findings, expression of endogenous DUX4 in FSHD muscle cells and the CIC-DUX4 fusion containing the DUX4 CTD in a sarcoma cell line inhibit IFNγ-induction of ISGs. Mouse Dux similarly interacted with STAT1 and suppressed IFNγ induction of ISGs. These findings identify an evolved role of the DUXC family in modulating immune signaling pathways with implications for development, cancers, and FSHD. ### Competing Interest Statement The authors have declared no competing interest.
13. Establishment of a novel human CIC-DUX4 sarcoma cell line, Kitra ...
1 nov 2019 · & Somers, G. R. The CIC-DUX4 fusion transcript is present in a subgroup of pediatric primitive round cell sarcomas. Hum. pathol. 43, 180–189 ...
Approximately 60–70% of EWSR1-negative small blue round cell sarcomas harbour a rearrangement of CIC, most commonly CIC-DUX4. CIC-DUX4 sarcoma (CDS) is an aggressive and often fatal high-grade sarcoma appearing predominantly in children and young adults. Although cell lines and their xenograft models are essential tools for basic research and development of antitumour drugs, few cell lines currently exist for CDS. We successfully established a novel human CDS cell line designated Kitra-SRS and developed orthotopic tumour xenografts in nude mice. The CIC-DUX4 fusion gene in Kitra-SRS cells was generated by t(12;19) complex chromosomal rearrangements with an insertion of a chromosome segment including a DUX4 pseudogene component. Kitra-SRS xenografts were histologically similar to the original tumour and exhibited metastatic potential to the lungs. Kitra-SRS cells displayed autocrine activation of the insulin-like growth factor 1 (IGF-1)/IGF-1 receptor (IGF-1R) pathway. Accordingly, treatment with the IGF-1R inhibitor, linsitinib, attenuated Kitra-SRS cell growth and IGF-1-induced activation of IGF-1R/AKT signalling both in vitro and in vivo. Furthermore, upon screening 1134 FDA-approved drugs, the responses of Kitra-SRS cells to anticancer drugs appeared to reflect those of the primary tumour. Our model will be a useful modality for investigating the molecular pathology and therapy of CDS.
